59 search results for: mechanism of disease

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

Type 2 Inflammation Alters the Structure and Function <b>of</b> the Skin in AD

expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in AD

28 min

Dermatology

Highlights from the WCD 2023 ADVENT symposium, analyzing case studies and linked comorbidities in relation to atopic dermatitis and prurigo nodularis.

expert video

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis

2 min

Dermatology

Dr. Stephan Weidinger explains how type 2 cytokines impact the skin microbiome in AD.

The Impact <b>of</b> Skin Dysbiosis on Atopic Dermatitis

expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

2 min

Dermatology

Dr. Lisa Beck highlights key data from the ADRN Study demonstrating the correlation between skin dysbiosis, S. aureus colonization, and atopic dermatitis severity.

The Impact <b>of</b> Type 2 Inflammation on the Neuroimmune Axis in AD

expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

10 min

Dermatology

Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.

interactivity

Lung Function Decline: Why it Matters and What’s at Stake for Patients

5 min

Pulmonology

Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .

expert video

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis

2 min

Dermatology

Dr. Amy Paller shares her opinion on practical considerations for evaluating response during treatment with biologics in children with atopic dermatitis.

The Implications <b>of</b> Sweat Duct Dysfunction and the Microbial Dysbiosis in AD

expert video

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD

3 min

Dermatology

Dr. Lisa Beck talks about sweat duct dysfunction and the impact of S. aureus colonization.

The Role <b>of</b> Epithelial Barrier Components in AD: Insights and Implications

expert video

The Role of Epithelial Barrier Components in AD: Insights and Implications

6 min

Dermatology

Dr. Lisa Beck explains the role of epithelial barrier components and barrier disruption in AD.

expert video

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

53 min

Dermatology

Highlights from the WCD 2023 ADVENT symposium, exploring the distinctions and shared elements of atopic dermatitis and prurigo nodularis.

The Role <b>of</b> Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

2 min

Dermatology

Dr. Robert Bissonnette highlights the role of type 2 inflammation in skin barrier dysfunction in atopic dermatitis.

interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

10 min

Dermatology

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Czech RepublicChange country/region